4D Path

📍 Newton, United States🗓 Founded 2016👥 18 employees💰 Last funded Apr 2022
Biotechnology Research🌐 4dpath.com
Website LinkedIn
4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly compute cell cycle deregulation and tumor microenvironment dynamics. By accurately predicting a patient’s response to therapy from routine biopsy images, QPOR™ enables precision treatment selection in ways not previously possible. This unprecedented view into tumor dynamics creates new pathways from clinical use to commercial application—bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in 4D Path?
4D Path has 1 investors on record on gritt.io and 1 late-stage investors.
When did 4D Path last raise funding?
The most recent investment in 4D Path recorded on gritt.io was in April 2022.
When was 4D Path founded?
4D Path was founded in 2016.
What industry is 4D Path in?
4D Path operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is 4D Path based?
4D Path is headquartered in Newton, United States.